ورود به حساب

نام کاربری گذرواژه

گذرواژه را فراموش کردید؟ کلیک کنید

حساب کاربری ندارید؟ ساخت حساب

ساخت حساب کاربری

نام نام کاربری ایمیل شماره موبایل گذرواژه

برای ارتباط با ما می توانید از طریق شماره موبایل زیر از طریق تماس و پیامک با ما در ارتباط باشید


09117307688
09117179751

در صورت عدم پاسخ گویی از طریق پیامک با پشتیبان در ارتباط باشید

دسترسی نامحدود

برای کاربرانی که ثبت نام کرده اند

ضمانت بازگشت وجه

درصورت عدم همخوانی توضیحات با کتاب

پشتیبانی

از ساعت 7 صبح تا 10 شب

دانلود کتاب Pharmacoepidemiology, Fourth Edition

دانلود کتاب فارماکوپیدمیولوژی، چاپ چهارم

Pharmacoepidemiology, Fourth Edition

مشخصات کتاب

Pharmacoepidemiology, Fourth Edition

ویرایش:  
 
سری:  
ISBN (شابک) : 9780470866818, 9780470059876 
ناشر:  
سال نشر:  
تعداد صفحات: 875 
زبان: English 
فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) 
حجم فایل: 26 مگابایت

قیمت کتاب (تومان) : 36,000



ثبت امتیاز به این کتاب

میانگین امتیاز به این کتاب :
       تعداد امتیاز دهندگان : 16


در صورت تبدیل فایل کتاب Pharmacoepidemiology, Fourth Edition به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.

توجه داشته باشید کتاب فارماکوپیدمیولوژی، چاپ چهارم نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.


توضیحاتی درمورد کتاب به خارجی

Content:
Chapter 1 What is Pharmacoepidemiology? (pages 1–15): Brian L. Strom
Chapter 2 Study Designs Available for Pharmacoepidemiology Studies (pages 17–28): Brian L. Strom
Chapter 3 Sample Size Considerations for Pharmacoepidemiology Studies (pages 29–36): Brian L. Strom
Chapter 4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies (pages 37–57): David A. Henry, Patricia McGettigan, Anne Tonkin and Sean Hennessy
Chapter 5 When Should One Perform Pharmacoepidemiology Studies? (pages 59–66): Brian L. Strom
Chapter 6 A View from Academia (pages 67–76): Robert M. Califf and Leanne K. Madre
Chapter 7 A View from Industry (pages 77–101): Robert F. Reynolds, Dale B. Glasser and Gretchen S. Dieck
Chapter 8 A View from Regulatory Agencies (pages 103–130): Peter Arlett, Jane Moseley and Paul J. Seligman
Chapter 9 Spontaneous Reporting in the United States (pages 131–159): Syed Rizwanuddin Ahmad, Roger A. Goetsch and Norman S. Marks
Chapter 10 Global Drug Surveillance: The WHO Programme for International Drug Monitoring (pages 161–183): I. Ralph Edwards, Sten Olsson, Marie Lindquist and Bruce Hugman
Chapter 11 Case–Control Surveillance (pages 185–202): Lynn Rosenberg, Patricia F. Coogan and Julie R. Palmer
Chapter 12 Prescription?Event Monitoring (pages 203–216): Saad A. W. Shakir
Chapter 13 Overview of Automated Databases in Pharmacoepidemiology (pages 217–222): Brian L. Strom
Chapter 14 Group Health Cooperative (pages 223–239): Kathleen W. Saunders, Robert L. Davis and Andy Stergachis
Chapter 15 Kaiser Permanente Medical Care Program (pages 241–259): Joe V. Selby, David H. Smith, Eric S. Johnson, Marsha A. Raebel, Gary D. Friedman and Bentson H. McFarland
Chapter 16 The HMO Research Network (pages 261–269): K. Arnold Chan, Robert L. Davis, Margaret J. Gunter, Jerry H. Gurwitz, Lisa J. Herrinton, Winnie W. Nelson, Marsha A. Raebel, Douglas W. Roblin, David H. Smith and Richard Platt
Chapter 17 UnitedHealth Group (pages 271–280): Deborah Shatin, Nigel S. B. Rawson and Andy Stergachis
Chapter 18 Medicaid Databases (pages 281–294): Sean Hennessy, Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom
Chapter 19 Health Services Databases in Saskatchewan (pages 295–310): Winanne Downey, Maryrose Stang, Patricia Beck, William Osei and James L. Nichol
Chapter 20 Automated Pharmacy Record Linkage in The Netherlands (pages 311–322): Hubert G. Leufkens and John Urquhart
Chapter 21 The Tayside Medicines Monitoring Unit (MEMO) (pages 323–336): Li Wei, John Parkinson and Thomas M. MacDonald
Chapter 22 The UK General Practice Research Database (pages 337–346): Joel M. Gelfand, David J. Margolis and Hassy Dattani
Chapter 23 Other Approaches to Pharmacoepidemiology Studies (pages 347–362): Brian L. Strom
Chapter 24 How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives (pages 363–374): Brian L. Strom
Chapter 25 National Medicinal Drug Policies: Their Relationship to Pharmacoepidemiology (pages 375–390): Suzanne Hill and David A. Henry
Chapter 26 Premarketing Applications of Pharmacoepidemiology (pages 391–400): Harry A. Guess
Chapter 27 Studies of Drug Utilization (pages 401–417): David Lee and Ulf Bergman
Chapter 28 Evaluating and Improving Physician Prescribing (pages 419–437): Sumit R. Majumdar, Helene Levens Lipton and Stephen B. Soumerai
Chapter 29 Drug Utilization Review (pages 439–453): Sean Hennessy, Stephen B. Soumerai, Helene Levens Lipton and Brian L. Strom
Chapter 30 Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety (pages 455–485): Robert T. Chen, Robert L. Davis and Philip H. Rhodes
Chapter 31 Pharmacoepidemiologic Studies of Devices (pages 487–500): Roselie A. Bright
Chapter 32 Studies of Drug?Induced Birth Defects (pages 501–514): Allen A. Mitchell
Chapter 33 Pharmacoepidemiology and Risk Management (pages 515–530): David J. Graham, Andrew D. Mosholder, Kate Gelperin and Mark I. Avigan
Chapter 34 The Use of Pharmacoepidemiology to Study Medication Errors (pages 531–538): Rainu Kaushal and David W. Bates
Chapter 35 Hospital Pharmacoepidemiology (pages 539–553): Brian L. Strom and Rita Schinnar
Chapter 36 Determining Causation from Case Reports (pages 555–570): Judith K. Jones
Chapter 37 Molecular Pharmacoepidemiology (pages 571–586): Stephen E. Kimmel, Hubert G. Leufkens and Timothy R. Rebbeck
Chapter 38 Bioethical Issues in Pharmacoepidemiologic Research (pages 587–598): David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan
Chapter 39 The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies (pages 599–610): Samuel M. Lesko and Allen A. Mitchell
Chapter 40 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects (pages 611–628): Brian L. Strom and Kenneth L. Melmon (the late)
Chapter 41 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals (pages 629–652): Kevin A. Schulman, Henry A. Glick and Daniel Polsky
Chapter 42 Using Quality?of?Life Measurements in Pharmacoepidemiologic Research (pages 653–663): Holger Schunemann, Gordon H. Guyatt and Roman Jaeschke
Chapter 43 N?of?1 Randomized Clinical Trials in Pharmacoepidemiology (pages 665–680): Gordon H. Guyatt, Roman Jaeschke and Robin Roberts
Chapter 44 The Use of Meta?analysis in Pharmacoepidemiology (pages 681–707): Jesse A. Berlin and Carin J. Kim
Chapter 45 Validity of Pharmacoepidemiologic Drug and Diagnosis Data (pages 709–765): Suzanne L. West, Brian L. Strom and Charles Poole
Chapter 46 Variable Compliance and Persistence with Prescribed Drug Dosing Regimens: Implications for Benefits, Risks, and Economics of Pharmacotherapy (pages 767–789): John Urquhart
Chapter 47 Bias and Confounding in Pharmacoepidemiology (pages 791–809): Ilona Csizmadi, Jean?Paul Collet and Jean?Francois Boivin
Chapter 48 Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis (pages 811–829): Samy Suissa
Chapter 49 The Future of Pharmacoepidemiology (pages 831–839): Brian L. Strom and Sean Hennessy



فهرست مطالب

PHARMACOEPIDEMIOLOGY Fourth Edition......Page 3
Contents......Page 7
List of Contributors......Page 11
Preface......Page 17
Acknowledgments......Page 21
PART I INTRODUCTION......Page 23
1. What is Pharmacoepidemiology?......Page 25
2. Study Designs Available for Pharmacoepidemiology Studies......Page 39
3. Sample Size Considerations for Pharmacoepidemiology Studies......Page 51
4. Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies......Page 59
5. When Should One Perform Pharmacoepidemiology Studies?......Page 81
PART II PERSPECTIVES ON PHARMACOEPIDEMIOLOGY......Page 89
6. A View from Academia......Page 91
7. A View from Industry......Page 99
8. A View from Regulatory Agencies......Page 125
PART III SOURCES OF DATA FOR PHARMACOEPIDEMIOLOGY STUDIES......Page 153
PART IIIa Ad Hoc Data Sources Available for Pharmacoepidemiology Studies......Page 155
9. Spontaneous Reporting in the United States......Page 157
10. Global Drug Surveillance: The WHO Programme for International Drug Monitoring......Page 183
11. Case–Control Surveillance......Page 207
12. Prescription-Event Monitoring......Page 225
PART IIIb Automated Data Systems Available for Pharmacoepidemiology Studies......Page 239
13. Overview of Automated Databases in Pharmacoepidemiology......Page 241
14. Group Health Cooperative......Page 245
15. Kaiser Permanente Medical Care Program......Page 263
16. The HMO Research Network......Page 283
17. UnitedHealth Group......Page 293
18. Medicaid Databases......Page 303
19. Health Services Databases in Saskatchewan......Page 317
20. Automated Pharmacy Record Linkage in The Netherlands......Page 333
21. The Tayside Medicines Monitoring Unit (MEMO)......Page 345
22. The UK General Practice Research Database......Page 359
PART IIIc Other Approaches to Pharmacoepidemiology Studies......Page 369
23. Other Approaches to Pharmacoepidemiology Studies......Page 371
24. How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives......Page 385
PART IV SELECTED SPECIAL APPLICATIONS OF PHARMACOEPIDEMIOLOGY......Page 397
25. National Medicinal Drug Policies: Their Relationship to Pharmacoepidemiology......Page 399
26. Premarketing Applications of Pharmacoepidemiology......Page 413
27. Studies of Drug Utilization......Page 423
28. Evaluating and Improving Physician Prescribing......Page 441
29. Drug Utilization Review......Page 461
30. Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety......Page 477
31. Pharmacoepidemiologic Studies of Devices......Page 509
32. Studies of Drug-Induced Birth Defects......Page 523
33. Pharmacoepidemiology and Risk Management......Page 537
34. The Use of Pharmacoepidemiology to Study Medication Errors......Page 553
35. Hospital Pharmacoepidemiology......Page 561
PART V SELECTED SPECIAL METHODOLOGIC ISSUES IN PHARMACOEPIDEMIOLOGY......Page 577
36. Determining Causation from Case Reports......Page 579
37. Molecular Pharmacoepidemiology......Page 593
38. Bioethical Issues in Pharmacoepidemiologic Research......Page 609
39. The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies......Page 621
40. The Use of Pharmacoepidemiology to Study Beneficial Drug Effects......Page 633
41. Pharmacoeconomics: Economic Evaluation of Pharmaceuticals......Page 651
42. Using Quality-of-Life Measurements in Pharmacoepidemiologic Research......Page 675
43. N-of-1 Randomized Clinical Trials in Pharmacoepidemiology......Page 687
44. The Use of Meta-analysis in Pharmacoepidemiology......Page 703
45. Validity of Pharmacoepidemiologic Drug and Diagnosis Data......Page 731
46. Variable Compliance and Persistence with Prescribed Drug Dosing Regimens: Implications for Benefits, Risks, and Economics of Pharmacotherapy......Page 789
47. Bias and Confounding in Pharmacoepidemiology......Page 813
48. Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis......Page 833
PART VI CONCLUSION......Page 853
49. The Future of Pharmacoepidemiology......Page 855
Appendix A Sample Size Tables......Page 863
Appendix B Glossary......Page 881
Index......Page 889




نظرات کاربران

تمامی حقوق معنوی و مادی وبسایت متعلق به اینترنشنال لایبرری می باشد
نماد اعتماد الکترونیکی